Percutaneous Radiofrequency Ablation and Transcatheter Arterial Chemoembolization for Hypervascular Hepatocellular Carcinoma: Rate and Risk Factors for Local Recurrence
- 351 Downloads
To analyze local recurrence-free rates and risk factors for recurrence following percutaneous radiofrequency ablation (RFA) or transcatheter arterial chemoembolization (TACE) for hypervascular hepatocellular carcinoma (HCC).
One hundred and nine nodules treated by RFA and 173 nodules treated by TACE were included. Hypovascular nodules were excluded from this study. Overall local recurrence-free rates of each treatment group were calculated using the Kaplan-Meier method. The independent risk factors of local recurrence and the hazard ratios were analyzed using Cox’s proportional-hazards regression model. Based on the results of multivariate analyses, we classified HCC nodules into four subgroups: central nodules ≤2 cm or >2 cm and peripheral nodules ≤2 cm or >2 cm. The local recurrence-free rates of these subgroups for each treatment were also calculated.
The overall local recurrence-free rate was significantly higher in the RFA group than in the TACE group (p = 0.013). The 24-month local recurrence-free rates in the RFA and TACE groups were 60.0% and 48.9%, respectively. In the RFA group, the only significant risk factor for recurrence was tumor size >2 cm in greatest dimension. In the TACE group, a central location was the only significant risk factor for recurrence. In central nodules that were ≤2 cm, the local recurrence-free rate was significantly higher in the RFA group than in the TACE group (p < 0.001). In the remaining three groups, there was no significant difference in local recurrence-free rate between the two treatment methods.
A tumor diameter of >2 cm was the only independent risk factor for local recurrence in RFA treatment, and a central location was the only independent risk factor in TACE treatment. Central lesions measuring ≤2 cm should be treated by RFA.
KeywordsChemotherapeutic embolization Hepatocellular carcinoma Liver neoplasms Radiofrequency (RF) ablation
- 1.Munoz N, Bosch X (1987) Epidemiology of hepatocellular carcinoma. In: Okuda L, Ishakk KG (eds). Springer, Berlin Heidelberg New York, pp 3–19Google Scholar
- 8.Bronowicki JP, Vetter D, Doffoel M (1997) Chemoembolization of hepatocellular carcinoma. In: Okuda K, Tabor E (eds) Liver cancer. Churchill Livingstone, New York, pp 463–469Google Scholar
- 9.Takayasu K, Shima Y, Muramatsu Y, et al. (1987) Hepatocellular carcinoma: Treatment with intraarterial iodized oil with and without chemotherapeutic agents. Radiology 162:345–351Google Scholar
- 13.SAS Institute (1990) SAS/STAT user’s guide, version 6, 4th edn. SAS Institute, Cary, NCGoogle Scholar
- 16.McGahan JP, Dodd GD III (2001) Radiofrequency ablation of the liver: Current status [review]. AJR Am J Roentgenol 176:3–16Google Scholar